OBJECTIVE: To conduct an open-label, multinational, multicenter study examining the safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in treatment of infantile-onset Pompe disease. STUDY DESIGN: We enrolled 8 infant patients who had Pompe disease with GAA activity <1% of normal, cardiomyopathy, and hypotonia. In the 52-week initial phase, rhGAA was infused intravenously at 10 mg/kg weekly; an extension phase continued survivors' treatment with 10 to 20 mg/kg of rhGAA weekly or 20 mg/kg every 2 weeks for as long as 153 weeks. Safety measurements included adverse events, laboratory tests, and anti-rhGAA antibody titers. Efficacy evaluations included survival, ventilator use, echocardiograms, growth, and motor and cognitive function. RESULT: After 52 weeks of treatment, 6 of 8 patients were alive, and 5 patients were free of invasive ventilator support. Clinical improvements included ameliorated cardiomyopathy and improved growth and cognition. Five patients acquired new motor milestones; 3 patients walked independently. Four patients died after the initial study phase; the median age at death or treatment withdrawal for all patients was 21.7 months, significantly later than expected for patients who were not treated. Treatment was safe and well tolerated; no death was drug-related. CONCLUSION: rhGAA improved ventilator-free survival, cardiomyopathy, growth, and motor function in patients with infantile-onset Pompe disease compared with outcomes expected for patients without treatment.
OBJECTIVE: To conduct an open-label, multinational, multicenter study examining the safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in treatment of infantile-onset Pompe disease. STUDY DESIGN: We enrolled 8 infantpatients who had Pompe disease with GAA activity <1% of normal, cardiomyopathy, and hypotonia. In the 52-week initial phase, rhGAA was infused intravenously at 10 mg/kg weekly; an extension phase continued survivors' treatment with 10 to 20 mg/kg of rhGAA weekly or 20 mg/kg every 2 weeks for as long as 153 weeks. Safety measurements included adverse events, laboratory tests, and anti-rhGAA antibody titers. Efficacy evaluations included survival, ventilator use, echocardiograms, growth, and motor and cognitive function. RESULT: After 52 weeks of treatment, 6 of 8 patients were alive, and 5 patients were free of invasive ventilator support. Clinical improvements included ameliorated cardiomyopathy and improved growth and cognition. Five patients acquired new motor milestones; 3 patients walked independently. Four patientsdied after the initial study phase; the median age at death or treatment withdrawal for all patients was 21.7 months, significantly later than expected for patients who were not treated. Treatment was safe and well tolerated; no death was drug-related. CONCLUSION: rhGAA improved ventilator-free survival, cardiomyopathy, growth, and motor function in patients with infantile-onset Pompe disease compared with outcomes expected for patients without treatment.
Authors: L Klinge; V Straub; U Neudorf; J Schaper; T Bosbach; K Görlinger; M Wallot; S Richards; T Voit Journal: Neuromuscul Disord Date: 2004-11-26 Impact factor: 4.296
Authors: F Martiniuk; A Chen; A Mack; E Arvanitopoulos; Y Chen; W N Rom; W J Codd; B Hanna; P Alcabes; N Raben; P Plotz Journal: Am J Med Genet Date: 1998-08-27
Authors: T Kikuchi; H W Yang; M Pennybacker; N Ichihara; M Mizutani; J L Van Hove; Y T Chen Journal: J Clin Invest Date: 1998-02-15 Impact factor: 14.808
Authors: A G Bijvoet; H Van Hirtum; M A Kroos; E H Van de Kamp; O Schoneveld; P Visser; J P Brakenhoff; M Weggeman; E J van Corven; A T Van der Ploeg; A J Reuser Journal: Hum Mol Genet Date: 1999-11 Impact factor: 6.150
Authors: M G Ausems; J Verbiest; M P Hermans; M A Kroos; F A Beemer; J H Wokke; L A Sandkuijl; A J Reuser; A T van der Ploeg Journal: Eur J Hum Genet Date: 1999-09 Impact factor: 4.246
Authors: Lakshya Bajaj; Jaiprakash Sharma; Alberto di Ronza; Pengcheng Zhang; Aiden Eblimit; Rituraj Pal; Dany Roman; John R Collette; Clarissa Booth; Kevin T Chang; Richard N Sifers; Sung Y Jung; Jill M Weimer; Rui Chen; Randy W Schekman; Marco Sardiello Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: Piers C A Barker; Sara K Pasquali; Stephen Darty; Richard J Ing; Jennifer S Li; Raymond J Kim; Stephanie DeArmey; Priya S Kishnani; Michael J Campbell Journal: Mol Genet Metab Date: 2010-07-23 Impact factor: 4.797
Authors: Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen Journal: Mol Genet Metab Date: 2010-01 Impact factor: 4.797